Market Place
Sourcing Support
Skye Bioscience Surpasses 50% Enrollment in Phase 2 Obesity Study
14 Nov 2024 //
GLOBENEWSWIRE
Skye Bioscience Report Q3 2024 Financial Results & Highlights
07 Nov 2024 //
GLOBENEWSWIRE
Skye Bioscience Achieves Weight Loss with CB1-Inhibiting Nimacimab
04 Nov 2024 //
GLOBENEWSWIRE
Skye Bioscience to Announce Third Quarter 2024 Results
01 Nov 2024 //
GLOBENEWSWIRE
Skye Bioscience Names Paul Grayson as Chairman of the Board
29 Oct 2024 //
GLOBENEWSWIRE
Skye Bioscience To Attend November Healthcare Investment Conferences
21 Oct 2024 //
GLOBENEWSWIRE
Skye Bioscience Comments On Monlunabant Phase 2 Results
23 Sep 2024 //
GLOBENEWSWIRE
Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer
03 Sep 2024 //
GLOBENEWSWIRE
Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences
26 Aug 2024 //
GLOBENEWSWIRE
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
23 Aug 2024 //
GLOBENEWSWIRE
Skye Bioscience Launches Phase 2 Trial Of Nimacimab For Obesity
22 Aug 2024 //
GLOBENEWSWIRE
Skye Bioscience Reports Q2 2024 Results And Recent Highlights
09 Aug 2024 //
GLOBENEWSWIRE
Skye Bioscience Hosts KOL Event On CB1 Inhibition And Phase 2 Trial
24 Jul 2024 //
GLOBENEWSWIRE
Skye Bioscience Forms Advisory Board For Nimacimab Development
11 Jul 2024 //
GLOBENEWSWIRE
Skye Bioscience To Host KOL Event On CB1 Inhibition On July 24
11 Jul 2024 //
GLOBENEWSWIRE
Skye Bioscience Appoints Dr. Karen Smith to Board of Directors
03 Jul 2024 //
GLOBENEWSWIRE
Skye Bioscience Added to Russell 2000® and Russell 3000® Indexes
01 Jul 2024 //
GLOBENEWSWIRE
Skye BioScience Participating in Piper Sandler Virtual Obesity Day
25 Jun 2024 //
GLOBENEWSWIRE
Skye ends eye disease R&D after glaucoma drug’s phase 2 fail
10 Jun 2024 //
FIERCE BIOTECH
Skye Bioscience to Present at Jefferies Global Healthcare Conference
03 Jun 2024 //
GLOBENEWSWIRE
Skye Bioscience Cannabinoid Library For Ocular Disease At ARVO
10 May 2024 //
GLOBENEWSWIRE
Skye Bio Two Posters at ARVO 2024
30 Apr 2024 //
GLOBENEWSWIRE
Skye Bioscience to Present at Upcoming Investment Conferences
23 Apr 2024 //
GLOBENEWSWIRE
Skye Bioscience uplists; OncoX`s licensing deal with ABVC BioPharma
10 Apr 2024 //
ENDPTS
Skye Bioscience Uplists to The Nasdaq Global Market
10 Apr 2024 //
GLOBENEWSWIRE
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors
04 Mar 2024 //
GLOBENEWSWIRE
Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100
26 Feb 2024 //
GLOBENEWSWIRE
Skye Announces Development Plan in Obesity for CB1 Inhibitor, Nimacimab
11 Dec 2023 //
GLOBENEWSWIRE
Skye Treats First Patient in Glaucoma Ph 2 Study of SBI-100 Ophthalmic Emulsion
28 Nov 2023 //
GLOBENEWSWIRE
Skye acquires Bird Rock Bio, weeks after Novo says it will buy a CB1 developer
21 Aug 2023 //
ENDPTS
Skye Bioscience closes enrolment in Phase I trial of SBI-100 OE
13 Jun 2023 //
CLINICAL TRIALS ARENA
FDA approves Skye Bioscience’s IND for glaucoma therapy trial
21 Dec 2022 //
CLINICALTRIALSARENA
Skye Bioscience Closes Acquisition of Emerald Health Therapeutics
11 Nov 2022 //
BIOSPACE
Skye Bioscience Completes Drug Production for Phase 1 Clinical Study
20 Sep 2022 //
GLOBENEWSWIRE
Skye Bioscience Files Definitive Proxy Statement and Announces Stockholder
01 Sep 2022 //
GLOBENEWSWIRE
Skye Bioscience Selects NextPharma as Phase 2 Contract Drug Manufacturer
21 Jul 2022 //
GLOBENEWSWIRE
Skye says its CMO was hit with cyberattack, resulting in clinical trial delays
20 Jul 2022 //
ENDPTS
Skye Bioscience Expands Cannabinoid Pharmaceutical Innovation Program
07 Jun 2022 //
GLOBENEWSWIRE
Skye Bioscience Signs Arrangement Agreement with Emerald Health Therapeutics
12 May 2022 //
GLOBENEWSWIRE
Skye Bio Reports Enhanced Intraocular Pressure-Lowering of SBI-100 Formulation
05 May 2022 //
GLOBENEWSWIRE
Skye Bio Engages Clinical Trial Site for Phase 1 Study in Agreement with CMAX
28 Apr 2022 //
GLOBENEWSWIRE
Skye Bio Retains Novotech as CRO for Phase 1 Trial of Glaucoma Drug Candidate
03 Mar 2022 //
GLOBENEWSWIRE
Skye Bioscience Reports Positive Results for SBI-100 in GLP Toxicology Study
16 Feb 2022 //
GLOBENEWSWIRE
Skye Bioscience Reports Potential Neuroprotective Benefit of SBI-100
01 Feb 2022 //
GLOBENEWSWIRE
Skye Bioscience Issues Shareholder Letter Providing Progress Update
10 Jan 2022 //
GLOBENEWSWIRE
Skye Bioscience Sponsored Research Presented at American Association
21 Oct 2021 //
GLOBENEWSWIRE
Skye Bioscience Establishes New Cannabinoid Pharmaceutical Innovation Program
12 Oct 2021 //
GLOBENEWSWIRE
Skye Bioscience Announces Closing of $7.0 M Registered Direct Offering
29 Sep 2021 //
GLOBENEWSWIRE
Skye Bioscience Announces $7.0 Million Registered Direct Offering
27 Sep 2021 //
GLOBENEWSWIRE
Skye Bioscience Announces Special Virtual Investor Presentation
14 Sep 2021 //
GLOBENEWSWIRE
Skye Bioscience Completes THCVHS IND-enabling In Vitro Genotoxicity Studies
10 Aug 2021 //
GLOBENEWSWIRE
